BBIO vs MDGL
BridgeBio Pharma, Inc. and Madrigal Pharmaceuticals, Inc., both Healthcare
BridgeBio Pharma, Inc. is the larger company at $14B against $12B. Over the past year BBIO returned +25% against +7.3% for MDGL. The RyuScore puts MDGL ahead, 11 against 7 out of 100.
| Figure | BBIO | MDGL |
|---|---|---|
| Last close | $65.35 | $472 |
| Market cap | $14B | $12B |
| 1-year return | +25% | +7.3% |
| 5-year return | +34% | +496% |
| RyuScoresector-relative, 1–10 | 7/100 | 11/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BridgeBio Pharma, Inc.
Revenue of $244M in Q2 2026, net income null. Its largest reported line is License Services And Royalty, 45% of the disclosed total.
Madrigal Pharmaceuticals, Inc.
Revenue of $364M in Q2 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.